To evaluate the effects of TRF on CDAHFD-induced NASH pathology, we measured plasma liver injury markers, ALT and AST activity, and lipid content in the liver and evaluated inflammatory response and hepatic fibrosis. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.